

AbbVie), Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, and Takeda, S. Mathew Grant / Research support from: Biohaven Pharmaceuticals, Boehringer-Ingelheim, Janssen, Merck, Sage Therapeutics, Inc., and VistaGen Therapeutics, Consultant of: Allergan (now AbbVie), Alkermes, Almatica Pharma, Axsome Therapeutics, BioXcel Therapeutics, Boehringer-Ingelheim, Clexio Biosciences, COMPASS Pathways, Eleusis, EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Perception Neurosciences, Praxis Precision Medicines, Neumora, Neurocrine, Relmada Therapeutics, Sage Therapeutics, Inc., Seelos Therapeutics, Signant Health, and Sunovion, S. Parikh Grant / Research support from: Aifred, Assurex, Janssen, Mensante, Sage Therapeutics, Inc., and Takeda, S. Aaronson Grant / Research support from: COMPASS Pathways and Neuronetics; has served as a consultant to Genomind, Inc., Janssen, LivaNova PLC, Neuronetics; and Sage Therapeutics, Inc., Speakers bureau of: Janssen and Sunovion Pharmaceuticals, Inc., B. Baune Speakers bureau of: Angelini, AstraZeneca, Biogen, Bristol Myers Squibb, Janssen, LivaNova, Lundbeck, Novartis, Otsuka, Pfizer, Servier, Sumitomo Pharma, Wyeth, and Boehringer-Ingelheim, A. Czysz Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., I. Nandy Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., V. Ona Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., C. Brown Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., S. Kyaga Employee of: Biogen Inc., F. Forrestal Employee of: Biogen Inc., S. Levin Employee of: Biogen Inc., J. Doherty Shareolder of: Sage Therapeutics, Inc., Employee of: Sage Therapeutics, Inc., G. Mattingly: None Declared

EPP0567

Exploring the impact of religiosity and spirituality on depressive symptoms in homeless people

P. H. F. Camargo^{1*}, J. V. G. N. de Moraes² and L. M. VITORINO²

¹Medicine, Faculty of Medicine of Itajubá and ²Medicine, Faculty of Medicine of Itajubá, Itajubá, Brazil

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.679

Introduction: Depression is a major concern among homeless individuals. Studies link religiosity and spirituality (RS) with lesser depressive symptoms, but evidence is scarce among the homeless.

Objectives: This study aims to assess the association between RS and depressive symptoms in homeless individuals in Brazil.

Methods: This cross-sectional study involved 456 homeless individuals in São Paulo, Brazil. It received approval from the Ethics and Research Committee of the Faculty of Medicine of Itajubá, Brazil. We used adjusted linear regression models to analyze the association between RS and participants' depressive symptoms. Depressive symptoms were assessed with the Patient Health Questionnaire-9 (PHQ-9). We used the P-DUREL to measure religiosity, FACIT-Sp12 for spirituality, and the Brief-RCOPE scale for religious-spiritual coping strategies.

Results: Out of 482 invited participants, 456 (94.6%) completed all questionnaires, mostly males (75%) with an average age of 44.53 (SD 12.62) years. About 49.6% had depressive symptoms (PHQ-9 ≥ 10 points). After controlling for sociodemographic and health variables, factors such as temple/church attendance (≥ 3 times

per month), increased religiousness (both organizational and intrinsic), positive religious/spiritual coping, and peace, faith and meaning were inversely related to depressive symptoms. Conversely, dysfunctional use of RS, such as in negative spiritual-religious coping strategies, correlated with heightened depressive symptoms.

Conclusions: High depressive symptom prevalence was found among Brazilian homeless individuals. Functional use of RS was negatively linked to depressive symptoms, while dysfunctional RS, like negative spiritual-religious coping strategies, correlated with higher depressive symptoms. These findings can aid healthcare professionals, particularly psychologists and psychiatrists, in addressing RS in the homeless population.

Disclosure of Interest: None Declared

EPP0568

Efficacy and acceptability of S-adenosyl-L-methionine (S-AMe) for depressed patients: a systematic review and meta-analysis of randomized controlled trials

N. Limveeraprajak^{1*}, S. Nakhawatchana¹, A. Visukamol¹, C. Siripakkaphant², S. Suttajit³ and M. Srisurapanont³

¹Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok; ²Faculty of Medicine and ³Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.680

Introduction: Current treatment options for depression remain unsatisfactory. S-AMe, a naturally occurring body chemical available as a dietary supplement, was discovered in the 1950s. S-AMe deficiency is associated with depression.

Objectives: This systematic review and meta-analysis aimed to investigate the efficacy and acceptability of S-AMe in treating patients with depression. The primary efficacy outcome was measured through the reduction in depression severity scores. All-cause dropout rates were assessed as indicators of treatment acceptability.

Methods: To include the randomized trials comparing S-AMe with other agents, we conducted a search on PubMed, Embase, and the Cochrane Library from their inception until April 27, 2023. The quality of trials was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). Depression severity and overall dropout rates were synthesized using a random-effect model for frequentist pairwise meta-analysis.

Results: We categorized 23 trials (N = 2,234) into 11 trials comparing S-AMe vs. placebo, 5 trials comparing S-AMe + antidepressant vs. placebo + antidepressants, and 7 trials comparing S-AMe vs. antidepressants. S-AMe demonstrated a significantly greater reduction in depressive symptoms compared to placebo (SMD = -0.58, 95%CI [-0.93; -0.23], I² = 68%), as can be seen in Figure 1. A trend was observed wherein S-AMe showed a lesser reduction in depressive symptoms compared to antidepressants (SMD = 0.06, 95%CI [-0.06; 0.18], I² = 49%). When administered alongside ongoing antidepressant treatment, S-AMe did not significantly differ from placebo in reducing depressive symptoms (SMD = -0.16, 95%CI [-0.44; 0.13], I² = 57%). In the subgroup analysis of 11 trials comparing S-AMe and placebo, it was found that while the intramuscular (SMD = -0.92, 95%CI [-1.39; -0.44]) and oral routes

(SMD = -0.66, 95%CI [-1.24; -0.08]) revealed the efficacy of SAME, the intravenous route did not exhibit the same efficacy (SMD = -0.16, 95%CI [-0.47; 0.14]). The efficacy of SAME was not influenced by factors such as physical illness, history of antidepressant nonresponse, proportion of females, age, duration and dosage of SAME supplementation, publication year, and baseline depression severity. There was no significant difference in dropout rates between SAME and controls.

Image:




Figure 1. SAME vs. Placebo

Conclusions: Limited evidence suggests that SAME is well accepted and effective in reducing depressive symptoms. However, its antidepressant effect may not be as strong as that of traditional antidepressants. Randomized-controlled trials comparing SAME to antidepressants in depressed patients, both with and without ongoing antidepressant use, are still necessary.

Disclosure of Interest: None Declared

COVID-19 and related topics

EPP0569

Surveillance and monitoring program of child neurodevelopment in population born during social confinement due to covid contingency: monteria-colombia experience

C. Otalvaro¹, A. Romero^{1*} and M. C. Florian²

¹Cordoba, Universidad de Córdoba and ²Cordoba, Georges Noble School, Monteria, Colombia

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.681

Introduction: The American Academy of Pediatrics reports an incidence of 1 in every 54 children (Council on Children with Disabilities, 2021). The unique circumstances surrounding children born in 2020, who have experienced the COVID-19 pandemic since birth, present a distinct set of challenges for their neurodevelopmental well-being. The pandemic has led to reduced opportunities for learning and social interaction, masking mandates, decreased social support for research, and the potential misattribution of Autism Spectrum Disorders ASD symptoms to the effects of social isolation.

Objectives: This study aims to develop such a program for children born during the COVID-19 pandemic (2020-2022).

Methods: All children born in March 2020 were included in the study. The initial assessment involved administering the ASQ-3 to evaluate their development across the specified domains. Diagnostic Evaluation: Among the population, 6% (4 children) displayed concerning signs on the ASQ-3, warranting further diagnostic evaluation by specialized health professionals for possible ASD.

Results: Early Intervention and School Monitoring: Of the remaining 72% (46 children), who did not require diagnostic evaluation, intervention guidelines were provided, both within the school environment and at home. These children were reevaluated after a three-month period. Follow-up in the School Environment: Those children who underwent reevaluation were categorized into three groups: Nine children fell into the “gray” category on the ASQ-3 and were subsequently referred for diagnostic evaluation. Thirty-seven children progressed to the “white” category on the ASQ-3 after receiving intervention guidelines in both school and home settings. The findings of this research underscore the potential impact of the COVID-19 pandemic on the neurodevelopment of children born in 2020. 6% of the evaluated population were referred for diagnostic evaluation due to signs of ASD, suggesting a potential association between the pandemic and an increased risk of ASD within this cohort. 72% of children who received intervention guidelines demonstrated significant improvements in their neurodevelopment, highlighting the critical role of early intervention and school-based monitoring.

Conclusions: Implementing support strategies within educational settings was linked to positive developments in neurodevelopmental outcomes. Consequently, school-based neurodevelopmental monitoring, complemented by cohesive curricular guidelines, emerges as a beneficial approach for enhancing child development outcomes. The ASQ-3, as a structured instrument, proves invaluable in facilitating neurodevelopmental surveillance within educational settings, particularly in contexts with high demand and limited access to specialized care.

Disclosure of Interest: None Declared

EPP0570

Psychological distress and coping strategies of hospital nurses during covid-19 pandemic in Greece

C. Papanthanasou^{1*} and K. C. Patithras²

¹Department of Psychology, Panteion University of Social and Political Sciences and ²Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.682

Introduction: Hospital nurses have played a crucial role during the covid-19 pandemic. Research demonstrates the extent to which nurses were experiencing acute stress and psychological distress during the waves of the pandemic.

Objectives: The purpose of this study was to assess the psychological distress (stress, depression, and anxiety) of nurses working in public hospitals in Greece during the covid-19 pandemic, to identify their coping strategies, and to explore the eventual